# Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

> **NCT06866795** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Geode Therapeutics Inc.** · enrollment: 42 (estimated)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** GT-220F capsule

## Key facts

- **NCT ID:** NCT06866795
- **Lead sponsor:** Geode Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06866795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06866795, "Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06866795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*